TWYNEO Drug Patent Profile

« Back to Dashboard

When do Twyneo patents expire, and what generic alternatives are available?

Twyneo is a drug marketed by Mayne Pharma and is included in one NDA. There are thirteen patents protecting this drug.

The generic ingredient in TWYNEO is benzoyl peroxide; tretinoin. One supplier is listed for this compound. Additional details are available on the benzoyl peroxide; tretinoin profile page.

DrugPatentWatch^® Generic Entry Outlook for Twyneo

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 29, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TWYNEO

US Patents:	13
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for TWYNEO

TWYNEO is protected by thirteen US patents.

This potential generic entry date is based on patent 12,053,546.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,295,935
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	10,653,899		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,491,163		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	11,071,878		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,070,629		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,357,602		Y
Mayne Pharma	TWYNEO	benzoyl peroxide; tretinoin	CREAM;TOPICAL	214902-001	Jul 26, 2021		RX	Yes	Yes	12,257,348		Y

International Patents for TWYNEO

When does loss-of-exclusivity occur for TWYNEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Eurasian Patent Organization

European Patent Office

Japan

Mexico

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TWYNEO around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	3069287
China	110891561
European Patent Office	3651755
Japan	2020527143
World Intellectual Property Organization (WIPO)	2019012536
Australia	2010337830
Brazil	112012012023

Supplementary Protection Certificates for TWYNEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1586316	122011100019	Germany		PRODUCT NAME: BROMFENAC (2-AMINO-3-(4-BROMOBENZOYL)PHENYLESSIGSAEURE); REGISTRATION NO/DATE: EU/1/11/692/001 20110518
1458369	122008000041	Germany		PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
0526708	C300097	Netherlands		PRODUCT NAME: BOSENTAN, DESGEWENST IN DE VORM VAN EEN ZOUT OF EEN HYDRAAT OF IN DE VORM VAN EEN ESTER VAN DE HYDROXYLGROEP VAN DE 2-HYDROXYETHOXY REST MET EEN ZUUR MET DE FORMULE R5-OH, WAARIN R5 EEN C1-7-ALKANOYL, BENZOYL, OF HETEROCYCLYCARBONYL VOORSTELT; NATL. REGISTRATION NO/DATE: U/1/02/220/001 - 005 20020515; FIRST REGISTRATION: CH IKS 58841 01 - 02 20020228
1458369	CA 2008 00029	Denmark		PRODUCT NAME: ADAPALEN, BENZOYLPEROXID
1586316	SPC/GB11/054	United Kingdom		PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
1458369	C01458369/01	Switzerland		PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009
0186118	SPC/GB05/029	United Kingdom		PRODUCT NAME: MESOTRIONE (2-(4-METHYLSULPHONYL-2-NITROBENZOYL)-1,3CYCLOHEXANEDIONE); REGISTERED: AU 2726 20001016; UK 0309 OF 2005 20050218

Investment Scenario and Fundamentals Analysis for TWYNEO

Last updated: February 19, 2026

What is TWYNEO?

TWYNEO (tirbanibulin), developed by Sandoz (a Novartis division), is a topical pharmaceutical approved in 2021 for the treatment of actinic keratosis. As a relatively new entrant, TWYNEO targets a niche dermatological condition through a novel mechanism of action.

Market Landscape and Competitive Position

Market Size and Growth

• Actinic keratosis affects approximately 58 million US adults, with an annual growth rate of approximately 4% (American Academy of Dermatology, 2022).
• The global market for actinic keratosis treatments was valued at $750 million in 2022 and is projected to reach around $1 billion by 2027, growing at 6% annually.

Competitors

• 5-fluorouracil (5-FU): Topical chemotherapy agent, generic available, annual sales exceeding $500 million worldwide.
• Imiquimod: Immune response modifier, approximately $350 million annually.
• Diclofenac gel: Non-steroidal anti-inflammatory, around $150 million annually.
• Photodynamic therapy: Less commoditized, but significant procedural landscape.

TWYNEO seeks to address limitations of current therapies, such as treatment duration and patient compliance, with a targeted 5-day topical regimen.

FDA Approval and Market Entry

• Approved in December 2021 for the treatment of actinic keratosis.
• Launched in the U.S. in Q2 2022; initial market penetration remains limited but expanding.

Clinical and Regulatory Fundamentals

Navigation of Regulatory Pathway

• FDA approval based on two pivotal Phase 3 trials demonstrating superior lesion clearance and tolerability.
• No significant post-marketing commitments reported; compliance with standard dermatological drug regulations.

Clinical Efficacy and Safety Profile

Endpoint	TWYNEO (tirbanibulin)	Comparators
Complete lesion clearance at Week 8	49% (Trial 1), 53% (Trial 2)	35-45% (standard treatments)
Local skin reactions	Mild to moderate	Similar to other topicals
Discontinuation rate due to adverse events	2%	Slightly higher for imiquimod

Patent Position

• Patent protection secured until 2030, with potential extension applications under consideration.
• No current generic threats exist.

Financial and Investment Fundamentals

Revenue Streams

• Initial revenue driven by prescription volume in dermatology clinics.
• Price positioning: TWYNEO priced at approximately $650 per treatment cycle, comparable to existing therapies.

Cost Structure

• Manufacturing costs are estimated at below $100 per unit due to the small molecule’s synthesis complexity.
• Marketing and sales expenses are projected at 20-25% of revenue, reflecting the niche market.

Market Adoption and Revenue Projections

Year	Estimated Prescriptions	Market Share	Revenue (USD millions)
2022	1 million	2%	65
2023	3 million	6%	195
2025	6 million	12%	390

Risks to Investment

• Market penetration: Slow uptake due to clinician familiarity with existing treatments.
• Pricing pressures: Competition may respond with lower prices.
• Regulatory: Potential for restrictions if adverse trend emerges.

Strategic Considerations

• Focus on educational campaigns emphasizing simplified treatment regime.
• Expansion into other dermatological indications under SPR (special pediatric registry) or 505(b)(2) pathways.
• Partnership opportunities with dermatology-focused distributors.

Conclusion

TWYNEO exhibits promising fundamentals, with manageable patent protection, superior clinical efficacy, and a strategic market niche. Its success hinges on effective commercialization, clinician adoption, and pricing stability amid existing therapies. It presents a moderate risk, high potential return profile for focused investors.

Key Takeaways

• TWYNEO targets a $750 million market with projected growth to $1 billion by 2027; it fills gaps in treatment duration and tolerability.
• FDA approval in late 2021 establishes regulatory credibility; early sales have begun, with rapid growth projections.
• Patent life until 2030 supports a window for market exclusivity.
• Revenue projections suggest reaching nearly $400 million annually by 2025 if market share targets are met.
• Competitive risks include established therapies with generic versions and clinician inertia.

FAQs

1. What differentiates TWYNEO from existing actinic keratosis treatments?
TWYNEO offers a 5-day topical regimen with a favorable safety profile, compared to longer courses or procedural therapies.

2. How sustainable is the patent protection for TWYNEO?
Patent protection extends until 2030, with opportunities for extension or formulation patents.

3. What are the key hurdles for market adoption?
Clinician familiarity with current treatments, reimbursement policies, and patient acceptance of the new regimen.

4. How does TWYNEO's efficacy compare to competitors?
Clinical trials show complete clearance rates of approximately 50%, outperforming some existing topical chemotherapies.

5. What strategic moves could impact TWYNEO’s market position?
Entry into additional indications, partnerships with dermatology networks, and aggressive educational campaigns will influence market penetration.

---

References

[1] American Academy of Dermatology Association. (2022). Actinic keratosis epidemiology. https://www.aad.org

[2] Market Data Forecast. (2022). Actinic keratosis treatments market. https://www.marketdataforecast.com

[3] U.S. Food and Drug Administration. (2021). TWYNEO (tirbanibulin) approval letter. https://www.fda.gov

[4] Novartis AG. (2022). TWYNEO prescribing information. https://www.novartis.com